Autoimmune and Cholestatic Liver Disease: Cholestatic Liver Disease: Diagnosis to the Itch

0:00Welcome to Board Pearls. This is episode two of three of the Autoimmune and Cholestatic Liver Disease chapter, in the Liver Disease module. This episode is primary biliary cholangitis, from diagnosis to the itch. A woman with itching and a cholestatic pattern shows what the immune system attacks, which three findings make the diagnosis without a biopsy, what else to look for, and why the alkaline phosphatase predicts her future. A woman with a negative antibody and another with a positive antibody and normal liver tests show the two edges of the diagnosis. A man a year into treatment shows how ursodeoxycholic acid works, how response is judged at twelve months, and what comes next now that obeticholic acid is gone, and a woman with ascites shows when transplant comes in. And a woman who itches despite good liver tests shows why itch doesn't track the disease, the stepped treatment, the timing mistake with cholestyramine, and when itch alone justifies a transplant.

0:55Here's the first patient. A fifty-two-year-old woman has had itching for six months, worst at night, and fatigue. She has dry eyes and a dry mouth. Her alkaline phosphatase is three hundred ten, about two and a half times normal. Her alanine aminotransferase, ALT, is sixty-five, her aspartate aminotransferase, AST, fifty-five, and her bilirubin normal. Her immunoglobulin M, IgM, is high. Her ultrasound shows normal bile ducts. Her total cholesterol is high, and she has yellow plaques on her eyelids. Her doctor has started talking about a liver biopsy and a statin.

1:32Itching, fatigue, a cholestatic pattern with a high IgM, and normal ducts in a middle-aged woman point to primary biliary cholangitis. It's a slowly progressive autoimmune disease of the small bile ducts. T cells attack the epithelium of the small intralobular bile ducts, producing a destructive, non-suppurative cholangitis that over years causes progressive duct loss and fibrosis. The main antigen is the E2 subunit of the pyruvate dehydrogenase complex on the inner mitochondrial membrane, the same antigen the M2 anti-mitochondrial antibody recognizes, so the anti-mitochondrial antibody, AMA, is aimed at the target the T cells attack.

2:16A few facts frame who gets it. The name changed from primary biliary cirrhosis at the request of patient groups, because most patients are diagnosed before cirrhosis. The incidence is roughly fifty per million a year, women outnumber men nine or ten to one, the mean age at diagnosis is forty to fifty, and the human leukocyte antigen type HLA-DR8 is the susceptibility allele.

2:40Her story fits the usual presentation. That presentation runs from abnormal liver tests in someone who feels well, an increasing share of new diagnoses, to fatigue and itching, which dominate early disease. The itching is worse at night, can come before the lab abnormalities, and often improves as cirrhosis advances, so less itching late in the disease isn't necessarily good news. Dry eyes and mouth, xanthelasma, and a high cholesterol are common, and her eyelid plaques are xanthelasma. The labs are cholestatic: a high alkaline phosphatase, aminotransferases under five times normal unless there's overlap with autoimmune hepatitis or advanced disease, a bilirubin that's normal or mildly raised until late disease, and a high IgM. She matches every line.

3:28She doesn't need the biopsy her doctor mentioned, because the diagnosis is made on labs alone in more than ninety-five percent of cases. Three findings make it: a positive AMA at a titer of one to forty or higher; an alkaline phosphatase above one and a half times the upper limit of normal; and an AST under five times normal with no other explanation. Together, the AMA and the alkaline phosphatase have a positive predictive value of ninety-eight percent, so a biopsy would add risk without adding information.

3:58Her ultrasound has excluded a dilated duct, and her AMA is positive at one to three hundred twenty. With an alkaline phosphatase over one and a half times normal and an AST of fifty-five, she has primary biliary cholangitis without a biopsy. An AST over five times normal would raise an overlap with autoimmune hepatitis, which occurs in about five percent of these patients, and that's when a biopsy is needed. Episode three covers the overlap.

4:29With the diagnosis made, the conditions that travel with it are looked for. About twenty percent of patients have another autoimmune disorder: thyroiditis, Sjogren syndrome, scleroderma, especially the variant called CREST, for calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia, Raynaud phenomenon on its own, rheumatoid arthritis, and the autoimmune hepatitis overlap. Osteoporosis becomes nearly universal as the disease advances, driven partly by impaired bone formation in cholestasis, so it's looked for from the start. Her dry eyes and mouth point to Sjogren syndrome, her thyroid function is checked, and she gets a bone density scan.

5:13Her cholesterol answers the statin question. The hyperlipidemia of this disease is dominated by lipoprotein X, which is generally not atherogenic, so her cholesterol and xanthelasma don't carry the usual cardiac risk. A statin is decided by her other risk factors, not by this number.

5:30When a biopsy is needed, it shows four stages. Stage one is the florid duct lesion: granulomatous, lymphocytic destruction of the small interlobular bile ducts, with intense portal inflammation around a damaged duct and no fibrosis. It's essentially diagnostic and can be seen at any stage. Stage two adds biliary piecemeal necrosis, with duct destruction and ductular proliferation together, and variable portal fibrosis. Stage three shows progressive duct loss and bridging fibrosis between portal tracts. Stage four is cirrhosis, where histology may not distinguish this disease from other causes without copper staining or the clinical context.

6:11Her natural history sets the goals of treatment. The asymptomatic phase averages about seventeen years from diagnosis to symptoms, with fibrosis progressing silently. The symptomatic phase is the period after cirrhosis, with intractable itching, jaundice, ascites, variceal bleeding, and the other complications, and mean survival from the start of that phase is about seven years. Her itching and fatigue are symptoms of early disease, but her bilirubin is normal and she has none of the complications of cirrhosis, so she's early, when treatment has the most to protect.

6:44The marker to follow comes from outcome data. The Global Primary Biliary Cholangitis, PBC, Study Group showed that progression tracks with the serum alkaline phosphatase and total bilirubin, and even an alkaline phosphatase of one to two times normal was linked to progression. So the modern goals are to lower the alkaline phosphatase toward normal and keep the bilirubin normal, and her alkaline phosphatase is the number that's followed. If she had cirrhosis, she'd need liver cancer surveillance every six months with ultrasound and alpha-fetoprotein, AFP.

7:17The second patient shows a diagnosis the AMA misses. A fifty-eight-year-old woman has the same picture, but her AMA is negative. About five to ten percent of primary biliary cholangitis is AMA-negative, with the same natural history and the same response to ursodeoxycholic acid. The diagnosis then needs a biopsy or, where available, anti-sp100 and anti-gp210 testing. Those antibodies are highly specific, about ninety-eight percent, but only about twenty-five percent sensitive, so a negative result doesn't exclude the disease. Her anti-gp210 is negative, her biopsy shows a florid duct lesion, and she's treated the same way.

8:00The third patient shows the opposite edge, an antibody without the disease. A forty-four-year-old woman has a positive AMA found during a rheumatology workup, with normal liver tests. An AMA alone isn't primary biliary cholangitis. About one in six thousand two hundred fifty adults is AMA-positive without disease, and only about one in six of those develops it over five years. She gets periodic liver tests, not a biopsy or treatment, and she's treated if her alkaline phosphatase rises above one and a half times normal.

8:33Every patient with the disease is treated, and the fourth patient shows how the response is judged. A sixty-one-year-old man was diagnosed a year ago, with a positive AMA and an alkaline phosphatase of four hundred twenty. He weighs eighty kilograms and has taken ursodeoxycholic acid, UDCA, at one thousand two hundred milligrams a day. Today his alkaline phosphatase is two hundred thirty, about two times normal. His AST and bilirubin are normal, and his FibroScan shows no cirrhosis. He feels well and thinks the drop from four hundred twenty means the drug is working.

9:09Whether he's right depends on what UDCA does and how response is measured. UDCA is a hydrophilic bile acid. It competitively replaces the more cytotoxic hydrophobic bile acids in the pool, stabilizes hepatocyte and bile duct cell membranes against detergent injury, stimulates bicarbonate secretion, the protective umbrella over the bile duct cells, and has mild anti-apoptotic and immunomodulatory effects. In short, it makes bile less damaging to the ducts the disease is attacking.

9:42The dose is thirteen to fifteen milligrams per kilogram a day, once daily or divided, for life. His eighty kilograms times fifteen is one thousand two hundred, a full dose, and a patient on half that dose hasn't failed UDCA but has been undertreated. Three randomized trials established that UDCA slows histologic progression, lowers the alkaline phosphatase, and improves transplant-free survival in responders to a level approaching that of the general population, and about two-thirds of patients respond.

10:12He may not be one of them. The third who don't respond carry a meaningfully higher risk of cirrhosis, transplant, and death, and they need more treatment. Response is judged after twelve months. Several validated criteria sets exist, including Paris one and two, Toronto, Rotterdam, Barcelona, and the GLOBE and United Kingdom PBC, UK-PBC, continuous risk scores. The simplest working cutoff is an alkaline phosphatase above one and a half to one point six seven times normal at twelve months, which is an inadequate response that triggers escalation, and any raised bilirubin also means an inadequate response. Paris two, often cited because it applies to early disease, defines response as an alkaline phosphatase under one and a half times normal, an AST under one and a half times normal, and a normal bilirubin at twelve months.

11:07His alkaline phosphatase of two times normal is above both cutoffs, so he's a non-responder. What counts is where the number landed, not how far it fell. A landing at one point four times normal with a normal AST and bilirubin would have been a response, with UDCA continued alone, and a raised bilirubin would mean non-response whatever the alkaline phosphatase.

11:29As a non-responder, he needs a second-line drug, and the choice has changed. Obeticholic acid, a farnesoid X receptor, FXR, agonist that suppresses bile acid synthesis through CYP7A1, was the original second-line drug, given accelerated approval in twenty sixteen. About half of treated patients reached its composite endpoint, an alkaline phosphatase under one point six seven times normal with at least a fifteen percent fall and a normal bilirubin. Itching was its dominant side effect, and a twenty twenty-one boxed warning barred it in decompensated cirrhosis and in compensated cirrhosis with portal hypertension after decompensations and deaths. It was withdrawn from the United States market in September twenty twenty-five at the request of the Food and Drug Administration, FDA, because of liver injury signals, and its approval was formally withdrawn in November twenty twenty-five. In the United States, it's now the wrong answer.

12:27The current second-line drugs are the two peroxisome proliferator-activated receptor, PPAR, agonists approved in twenty twenty-four. Elafibranor activates PPAR alpha and delta, and in UDCA non-responders with an alkaline phosphatase over one point six seven times normal, about half reached the composite biochemical endpoint at twelve months, with a response within four weeks that was sustained. Seladelpar, a more selective PPAR delta agonist, produced a biochemical response in about sixty percent at twelve months. Both tend to improve itching rather than worsen it, significantly with seladelpar and non-significantly with elafibranor. Both are options for UDCA non-responders and for patients who can't tolerate UDCA, and the choice rests on side effects and tolerability.

13:15Off label, there are fibrates. Bezafibrate, a non-selective PPAR agonist, normalized the alkaline phosphatase in about two-thirds of patients as a UDCA add-on in a French trial, with less itching, but it isn't available in the United States. Fenofibrate, one hundred sixty milligrams a day, is an alternative, with adverse events more common in cirrhosis.

13:39He doesn't itch and has no cirrhosis, so either approved PPAR agonist is reasonable, and he starts seladelpar. He keeps his UDCA, because both PPAR agonists were studied as add-ons to it, not replacements. Six months later his alkaline phosphatase is one hundred forty, just above normal, with a normal bilirubin. A patient who can't tolerate UDCA, from severe nausea or diarrhea, moves to elafibranor or seladelpar without waiting twelve months.

14:12Beyond the liver drugs, every patient needs the same supportive care. Bone density is checked at diagnosis and periodically, everyone gets adequate calcium and vitamin D, and bisphosphonates treat established osteoporosis. His scan shows osteopenia, so he takes calcium and vitamin D and is rescanned. The fat-soluble vitamins A, D, E, and K are replaced when malabsorption develops with advancing cholestasis. And because the hyperlipidemia, dominated by lipoprotein X and high-density lipoprotein, HDL, doesn't generally raise cardiovascular risk, a statin isn't mandatory without other risk factors.

14:51Some patients progress despite treatment, and the fifth patient shows when transplant comes in. A sixty-six-year-old woman with primary biliary cholangitis has decompensated cirrhosis with ascites, which makes her a transplant candidate. Transplant is reserved for decompensated cirrhosis, for itching that's refractory despite every stage of therapy, for hepatocellular carcinoma within the Milan criteria, and, in selected centers, for intractable fatigue with severe impairment of quality of life. She's referred on her clinical picture, because these patients tend to be transplanted at a lower Model for End-Stage Liver Disease, MELD, score, which underestimates the disability of cholestasis. She has liver cancer surveillance every six months while she waits. Chapter twenty-four covers transplant.

15:35The last patient shows that the itch has to be treated on its own terms. A forty-eight-year-old woman with primary biliary cholangitis has a near-normal alkaline phosphatase on UDCA, but she itches all over, worst in bed at night, with scratch marks on her arms and legs. She sleeps four hours a night and has stopped working. She takes UDCA, levothyroxine, and vitamin D, all with breakfast, and she asks why she itches when her liver tests are so good.

16:02She has cholestatic pruritus, and her good liver tests don't protect her from it. Pruritus is the most common symptom of primary biliary cholangitis, often comes before the lab abnormalities, and in many patients worsens disability more than fatigue does. The mechanism is incompletely understood and probably multifactorial: retained bile acids accumulate, lysophosphatidic acid is the leading suspected pruritogen, endogenous opioids heighten itch perception in the brain, and bombesin-like peptides are implicated. It's worst at night, generalized rather than following a dermatome, and often improves as cirrhosis advances.

16:39That's why her itch doesn't track her disease. Her response to UDCA controls the duct injury but not the itch, and fading itch can even mean advancing disease. Treatment is stepped, with each step targeting a different mechanism, so failing one step doesn't mean failing the approach.

16:56Her first step is cholestyramine, a bile acid sequestrant that binds bile acids in the gut. The dose is four grams by mouth up to four times a day, to a maximum of sixteen grams, with relief over days to a couple of weeks. Constipation and the gritty preparation can limit tolerance, and colestipol and colesevelam are alternatives.

17:18The timing is where it goes wrong. Cholestyramine also binds UDCA, levothyroxine, the fat-soluble vitamins, and, historically, obeticholic acid, so it's given at least one hour before or four hours after other oral drugs. Taken with her breakfast drugs, it would fail to relieve her itch, raise her alkaline phosphatase by blocking UDCA absorption, and unsettle her thyroid tests, and the fix is separation, not a different drug. She takes it before lunch and dinner, with her other drugs kept at breakfast, and goes up to three doses a day, all spaced from breakfast. After three weeks her itching is a little better, but she still can't sleep.

18:02Her second step is rifampin, a pregnane X receptor agonist that induces hepatic CYP3A4, shifts bile acid metabolism, and may alter gut bacteria to reduce secondary bile acid production. The dose is one hundred fifty to three hundred milligrams twice a day, or one hundred fifty once a day titrated up. Idiosyncratic liver injury occurs in about five to twelve percent and can be severe, so liver tests are checked at four to eight weeks and periodically after, and the drug is stopped at any sign of worsening hepatitis or a rising bilirubin. She starts one hundred fifty milligrams twice a day and sleeps six hours, but at six weeks her ALT has doubled and her bilirubin has started to rise. Rifampin stops, her tests return to baseline in two weeks, and her itching comes back.

18:51Her third step targets the brain. Naltrexone, twelve and a half to fifty milligrams a day, blocks the opioid contribution to itch. It's started low, because some patients have an abrupt reaction like opioid withdrawal within hours of the first dose, which is self-limited and usually resolves over about a week, so patients are warned before the first dose. Sertraline, seventy-five to one hundred milligrams once a day, works through central serotonergic modulation and is favored when depression coexists. She's been low and tearful since she stopped working, so she starts sertraline, and naltrexone is added at twelve and a half milligrams, rising slowly.

19:41The warning matters, and another patient shows why. A sixty-year-old woman started on naltrexone at fifty milligrams developed sweating, nausea, cramps, and anxiety within hours, and she thinks she's allergic. She isn't. It's the withdrawal-like reaction, and she can continue, or restart at a low dose and titrate.

19:51Her next option is the newest class, the ileal bile acid transporter inhibitors. They block sodium-dependent bile acid uptake in the terminal ileum, so more bile acid is lost in the stool and the pool shrinks. Linerixibat was approved by the FDA in March twenty twenty-six for cholestatic itch in primary biliary cholangitis, with improvement by week two that was sustained over twenty-four weeks, and it's taken twice a day before food. Maralixibat is approved for cholestatic itch in Alagille syndrome and progressive familial intrahepatic cholestasis, and odevixibat for progressive familial intrahepatic cholestasis. Diarrhea and abdominal pain limit the dose, the expected result of more bile acid reaching the colon.

20:34The PPAR agonists, especially seladelpar, and the fibrates also help itch, so a patient who needs both biochemical escalation and itch relief can get both from one drug. Her itch still wakes her on sertraline and naltrexone, so she starts linerixibat, and by the end of the month she sleeps through the night.

20:53When all of that fails, a few options remain. Ultraviolet B phototherapy, plasmapheresis, and the molecular adsorbent recirculating system, MARS, are reserved for highly refractory itch. Severe refractory pruritus is a stand-alone transplant indication in well-selected patients, and cholestatic indications can drive listing at a lower MELD than synthetic failure would need. So a patient whose liver is otherwise doing well can still be a transplant candidate because of the itch.

21:22Here are the traps the boards set in these patients. A patient who meets the three lab criteria doesn't need a biopsy. A negative AMA doesn't rule out the disease, and neither does a negative anti-sp100 or anti-gp210. A positive AMA with normal liver tests is monitored, not treated. Sjogren syndrome, thyroid disease, and osteoporosis are looked for. The high cholesterol doesn't carry the usual cardiac risk. And a mildly high alkaline phosphatase isn't harmless.

21:52The treatment traps follow. UDCA isn't underdosed or stopped. Response isn't judged before twelve months, and a falling alkaline phosphatase isn't a response until it's checked where it landed. A raised bilirubin means non-response. Obeticholic acid is no longer available in the United States. UDCA continues when a second-line drug is added. And a cholestatic patient isn't kept waiting for the MELD to rise before transplant referral.

22:19The itch traps close the list. Itch doesn't track disease activity, and fading itch doesn't mean improvement. Cholestyramine isn't taken with UDCA, levothyroxine, or vitamins. Rifampin needs liver tests at four to eight weeks, and it stops when the bilirubin rises. Naltrexone starts low with a warning about the withdrawal-like reaction, which isn't an allergy. The PPAR agonists don't worsen itch. And refractory itch alone can justify a transplant.

22:48So, start to finish. Primary biliary cholangitis is autoimmune destruction of the small bile ducts, mostly in middle-aged women, aimed at a mitochondrial enzyme the AMA recognizes. Diagnose it without a biopsy when the AMA is positive, the alkaline phosphatase is over one and a half times normal, and the aminotransferases are under five times normal, and biopsy when an overlap is possible. AMA-negative disease needs anti-sp100, anti-gp210, or a biopsy and behaves the same, and a positive AMA with normal liver tests is monitored. Look for Sjogren syndrome, thyroid disease, and osteoporosis.

23:28Start every patient on UDCA, thirteen to fifteen milligrams per kilogram a day, for life, and judge response at twelve months: an alkaline phosphatase above about one point six seven times normal, or any raised bilirubin, means an inadequate response. Add elafibranor or seladelpar for non-responders and use them for UDCA intolerance, with bezafibrate or fenofibrate off label. Refer for transplant on the clinical picture, not the MELD.

23:58Treat itch in steps: cholestyramine spaced from other drugs, then rifampin with liver tests at four to eight weeks, then naltrexone started low, or sertraline when depression coexists, with linerixibat now an option. And consider transplant for refractory itch.

24:15Episode three is primary sclerosing cholangitis, immunoglobulin G4, IgG4, related disease, and the overlap syndromes.

24:24For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode two of three of chapter twenty, and I'll see you in the next one.